

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-91. (Canceled)

92. (Currently Amended) A method for the ~~accelerated~~ production of transgenic animals comprising:

a) transfecting a first non-human differentiated somatic cell or cell-line with a transgene construct containing a first DNA sequence;

b) selecting a transfected cell or cell-line into which said first DNA sequence has been inserted into the genome of said first non-human differentiated somatic cell or cell-line;

c) performing a first nuclear transfer procedure to generate a first transgenic animal at least heterozygous for said first DNA sequence;

d) performing a biopsy or other cell selection technique to obtain cells to establish a second non-human differentiated somatic cell or cell-line from said first transgenic animal;

e) characterizing said second non-human differentiated somatic cell or cell-line using ~~known~~ molecular biology methods to ensure that the ~~selected said~~ second non-human differentiated somatic cell or cell-line is at least heterozygous for said first DNA sequence; and

f) performing a second nuclear transfer procedure with at least one one cell of said second non-human differentiated somatic cell[[s]] or cell-line to produce at least a second transgenic animal at least heterozygous for said first DNA sequence; and

g) producing the second transgenic animal.

93. (Previously Presented) The method of claim 92, wherein said first transgenic animal is at an embryonic stage of development.

94. (Previously Presented) The method of claim 92, wherein said first transgenic animal is at a fetal stage of development.

95. (Previously Presented) The method of claim 92, further comprising developing said first transgenic animal into an adult non-human animal.

96. (Previously Presented) The method of claim 92, wherein said first transgenic animal is a mammal.

97. (Previously Presented) The method of claim 92, wherein said first DNA sequence encodes a desired protein.

98. (Previously Presented) The method of claim 92, wherein the genetic composition of said first transgenic animal is characterized to confirm the presence and expression of the transgene.

99. (Previously Presented) The method of claim 92, wherein said first nuclear transfer procedure further comprises transferring the nucleus of said transfected cell into a suitable enucleated recipient cell of the same species, thereby obtaining a reconstituted cell.

100. (Previously Presented) The method of claim 92, wherein said first transgenic animal is biopsied so as to characterize the genome of said first transgenic animal.

101. (Currently Amended) The method of claim 92, wherein at least one ~~of the cell~~[[s]] from said second non-human differentiated somatic cell or cell-line is expanded through cell culture techniques for use in said second round of nuclear transfer so as to produce a multiplicity of animals transgenic for said DNA of interest.

102. (Previously Presented) The method of claim 96, wherein the source of said differentiated somatic cell or cell-line is an ungulate.

103. (Currently Amended) The method of ~~either claim~~[[s]] 102, wherein said ~~differentiated somatic cell or cell-line is from an~~ ungulate is selected from the group consisting of bovine, ovine, porcine, equine, caprine and buffalo.

104. (Currently Amended) A method of preparing a genetically engineered transgenic mammal, comprising:

(a) inseminating a first female non-human mammal recipient with semen from a transgenic non-human animal of the same species known to have a transgene present and expressed;

(b) obtaining a transgenic non-human embryo from said first female recipient;

(c) obtaining a somatic cell from said embryo;

(d) culturing said differentiated somatic cell in a suitable medium, such that a differentiated somatic cell line is obtained and,

(e) performing a nuclear transfer procedure with said ~~non-human~~ differentiated somatic cells to produce at least one transgenic mammal at least heterozygous for said ~~first DNA sequence~~transgene[[;]], wherein said ~~first DNA sequence~~transgene encodes[[ing]] a desired gene ~~is~~ actuated by a tissue specific promoter;

(f) producing the transgenic mammal.

105. (Canceled) ~~The resultant offspring of the methods of claim 104.~~

106. (Currently Amended) The method of claim 92, wherein said second non-human differentiated somatic cell or cell-line ~~cells are~~is obtained from an embryonic goat on or after day 10 of embryogenesis.

107. (Currently Amended) The method of claim 92, wherein said second non-human differentiated somatic cell or cell line ~~preparation~~is kept in an airtight container.

108. (Currently Amended) The method of claim 92, wherein said first DNA sequence codes for a biopharmaceutical protein product.

109. (Currently Amended) The method of claim 108, wherein said first DNA sequence encodes[[ing]] a desired gene that is actuated by at least one beta casein promoter.

110. (Canceled) ~~The resultant milk derived from the offspring of the methods of claim 108.~~

111. (Currently Amended) The method of claim 92, wherein said second non-human differentiated somatic cell or cell-line is obtained from said first transgenic animal by ~~known~~ tissue dissociation means including enzymatic means and/or mechanical means.

112. (Currently Amended) The method of claim 92, wherein said second non-human differentiated somatic cell ~~or cell-line is selected from a group of cell types present in said first transgenic animal including:~~ a) fibroblast[[s]], [[b]] cumulus cell[[s]], [[c]] neural cell[[s]], [[d]] mammary cells; ~~and e) or a myocyte[[s]] or said second non-human differentiated somatic cell-~~ line is from a fibroblast, cumulus cell, neural cell, mammary cell or a myocyte.

113. (Canceled) ~~The resultant offspring of the method[[s]] of claim 92.~~

114. (Currently Amended) The method of claim 104, wherein said transgene codes for a biopharmaceutical protein product.

115. (Currently Amended) The method of claim 114, wherein said tissue specific promoter is a beta casein promoter.

116. (Canceled) ~~The resultant milk derived from the offspring of the methods of claim 114.~~

117. (Currently Amended) The method of claim 104, wherein said second non-human differentiated somatic cell or cell-line is obtained from said first transgenic animal by ~~known~~ tissue dissociation means including enzymatic means and/or mechanical means.

118. (Currently Amended) The method of claim 104, wherein said second non-human differentiated somatic cell ~~or cell-line is selected from a group of cell types present in said first transgenic animal including:~~ a) fibroblast[[s]], [[b]] cumulus cell[[s]], [[c]] neural cell[[s]], [[d]]

]]mammary cells; and e) or a myocyte[[s]] or said second non-human differentiated somatic cell-line is from a fibroblast, cumulus cell, neural cell, mammary cell or a myocyte.

119. (Previously Presented) The method of claim 92, wherein said transgene construct comprises a nucleic acid sequence encoding a human polypeptide.

120. (Previously Presented) The method of claim 92, wherein said transgene construct is capable of knocking out the expression of a gene endogenous to said first transgenic animal.

121. (Previously Presented) The method of claim 119, wherein said transgene construct further comprises a promoter wherein the nucleic acid is under the control of said promoter.

122. (Previously Presented) The method of claim 121, wherein said promoter is a tissue specific promoter.

123. (Previously Presented) The method of claim 122, wherein said tissue-specific promoter is a promoter preferentially expressed in mammary gland epithelial cells.

124. (Previously Presented) The method of claim 123, wherein said promoter is selected from the group consisting of a beta-casein promoter, beta-lactoglobulin promoter, whey acid protein promoter and lactalbumin promoter.

125. (Previously Presented) The method of claim 121, wherein said promoter is a caprine promoter.

126. (Previously Presented) The method of claim 119, wherein said nucleic acid encodes a polypeptide selected from the group consisting of a hormone, an immunoglobulin, a plasma protein, and an enzyme.

127. (Previously Presented) The method of claim 119, wherein said nucleic acid encodes a polypeptide selected from the group consisting of an alpha-1 proteinase inhibitor, an alkaline phosphatase, an angiogenin, an extracellular superoxide dismutase, a fibrogen, a glucocerebrosidase, a glutamate decarboxylase, a human serum albumin, a myelin basis protein, a proinsulin, a soluble CD4, a lactoferrin, a lactoglobulin, a lysozyme, a lactoalbumin, an erythropoietin, a tissue plasminogen activator, a human growth factor, an antithrombin III, an insulin, a prolactin, and an alpha-1-antitrypsin.

128. (Currently Amended) The method of claim 92, wherein said second non-human differentiated somatic cell ~~or cell-lines are~~ is a fibroblast[[s]] or said second non-human differentiated somatic cell-line is from a fibroblast.

129. (Currently Amended) The method of claim 128, wherein said fibroblasts ~~are~~ is a primary fibroblast[[s]].

130. (Currently Amended) The method of claim 128, wherein said fibroblast-s ~~are~~ is a primary derived fibroblast[[s]].